Golden Tate signed with the New York Giants this offseason, but his debut with the team will be put on hold once the regular season starts by four games. That’s because Tate has been handed a suspension from the league for a drug the wide receiver says he took under the prescription of a family-planning specialist but discontinued as soon as he discovered it included a substance on the NLF’s banned list.
My statement. pic.twitter.com/WzP7W4bclB
— Golden Tate (@ShowtimeTate) July 27, 2019
At least from Tate’s perspective, he self-reported the usage of the drug upon discovering it was outlawed by the league. If that is indeed how it played out (and there’s no reason to believe otherwise), the wide receiver may be in a good position to get the suspension shortened through the appeal process.
The Giants’ post-Odell Beckham Jr. receiving corps has been dealt blow after blow recently. Sterling Shepard fractured his thumb. Corey Coleman tore his ACL. And now Tate will miss four games (pending appeal).
Tate agreed to a four-year, $37 million contract ($23 million guaranteed) in May.
The 30-year-old Tate played eight games with the Eagles last season after being traded to Philadephia from the Detroit Lions, where he played from 2013. Prior to the Lions, Tate played his first four NFL years in Seattle.
For his career, Tate has 611 catches on 904 targets for 7,214 yards and 38 touchdowns. In 2014, he was selected to the Pro Bowl.
